Saxenda(Liraglutide)

Saxenda (Liraglutide) is a prescription injectable medication developed by Novo Nordisk for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have weight-related medical problems such as type 2 diabetes, hypertension, or high cholesterol. It is also approved for use in adolescents aged 12 to 17 years who are obese and weigh more than 60 kg (132 lbs).

The active ingredient, liraglutide, is a GLP-1 (glucagon-like peptide-1) receptor agonist that works by mimicking a natural hormone involved in appetite control and food intake regulation. By slowing gastric emptying and signaling feelings of fullness to the brain, Saxenda helps users eat less and achieve sustainable weight loss when used with a reduced-calorie diet and increased physical activity.

Key Features:

• Active ingredient: Liraglutide

• Indication: Chronic weight management in adults and eligible adolescents with obesity or overweight and related health conditions

• Administration: Subcutaneous injection, once daily

• Mechanism of Action: GLP-1 receptor agonist that suppresses appetite and helps control calorie intake

• Benefits:

  • Clinically proven weight loss results

  • Daily dosing for consistent appetite regulation

  • Supports improvements in overall metabolic health

Important Note:
Saxenda is not indicated for the treatment of type 1 or type 2 diabetes. It should be prescribed and monitored by a qualified healthcare professional as part of a comprehensive weight management program that includes a healthy diet and physical activity